S

ubscribing to the notion that the best defense is a good offense, Johnson & Johnson (JNJ) is appealing directly to large swaths of the public not to believe claims made by Pfizer (PFE) in a lawsuit that the health care giant used illegal tactics to protect a best-selling drug.

In a missive posted on its web site late last week and addressed to patients, doctors, insurers, and employers, J&J argued that Pfizer is, essentially, whining about an inability to successfully capture market share for its biosimilar version of Remicade, a blockbuster treatment for rheumatoid arthritis and other diseases.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • As I may have previously observed, the Pfizer approach seems mild compared to the J&J measures again Abbott for Humira, pre-AbbVie, some years ago. That is, at least, one person’s observation. I would be curious to see what “oii” (of happy memory) might think.

Sign up for our Biotech newsletter — The Readout

Your daily guide to what’s new in biotech.

X